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Abstract We conducted by bisulfite genomic sequencing a high
resolution study of the methylation of the galectin-1 gene in
expressing and nonexpressing tissues. We show that : (i)
hypomethylation of galectin-1 promoter correlates with expres-
sion; (ii) differences in methylation occur in a small region, which
include a CpG cluster; (iii) the density of methyl-CpGs rather
than site-specific methylation distinguishes the nonexpressing
from the expressing alleles ; (iv) the modification profiles in
nonexpressing tissues are highly heterogeneous; (v) a single CpG
within 1300 bp is always methylated both in expressing and
nonexpressing tissues; (vi) these features are conserved in rat and
mouse.
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1. Introduction
Galectin-1 is one of the best characterized galectins, a fam-
ily of animal lectins that share binding speci¢city for L-galac-
toside containing carbohydrates [1,2]. A variety of biological
functions, both during development and in adult tissues, has
been attributed to galectin-1. Its role in cell-cell and cell-ma-
trix interactions is well established [1]. However, a body of
evidence suggests that galectin-1 is also involved in the regu-
lation of cell growth [3,4], in neoplastic transformation [4^8],
in myoblast di¡erentiation [9] and in the maturation of
T-limphoblastoid cells [10]. Recently, galectin-1 has been iden-
ti¢ed as a mediator of T-cell and thymocyte apoptosis [11], as
an essential factor for neurite outgrowth and correct axonal
guidance in the developing olfactory system [12] and as a
required factor in the splicing of nuclear pre-mRNA [13].
The galectin-1 gene is developmentally and tissue speci¢-
cally regulated [1,14]. In liver, thyroid, cerebellum and brain,
galectin-1 mRNA levels are barely detectable while galectin-1
expression is very high in heart and in skeletal muscle [1,15].
Abnormal galectin-1 expression has been found during cell
dedi¡erentiation and in neoplastic cells. In general, galectin-
1 expression increases several fold with loss of di¡erentiation
[8,16,17] or with cell transformation [1,5,7,8,18] thereby con-
ferring a high metastatic potential on neoplastic cells [5,19].
The molecular mechanisms governing modulation of the
transcriptional activity of the galectin-1 gene have only re-
cently been investigated [20^22]. A small region (from position
350 to +50) of the galectin-1 promoter is su⁄cient to drive
e⁄cient transcription. Moreover, galectin-1 promoter con-
structs, containing up to 2500 bp upstream from the tran-
scription initiation site, are transactivated by factors present
in expressing and nonexpressing cells [21]. We previously
found a positive correlation between hypomethylation of the
galectin-1 promoter region and galectin-1 expression in vari-
ous cell lines. We also showed that reactivation of the silent
galectin-1 alleles in cell hybrids [20] is accompanied by a tran-
sition from a fully methylated to a fully unmethylated state of
several CpG dinucleotides in the promoter region [22]. A con-
troversial issue of this kind of study is whether changes in the
pattern of DNA methylation observed in cultured cells re£ect
physiologically relevant processes occurring in animal tissues
[23,24]. To address this question we de¢ned the precise meth-
ylation map of the gene in various rat and mouse adult tis-
sues. We found that the methylation state correlates with gene
expression also in tissues. However, while in cell lines di¡er-
ences in methylation were spread over a large area, in tissues
di¡erences in CpG modi¢cation were con¢ned to a cluster of
11 CpGs surrounding the transcription start site. In addition,
while in cell lines methylation was an all or none phenomenon
[22], nonexpressing tissues exhibited highly heterogeneous
methylation pro¢les and a single CpG site was constantly
methylated also in expressing tissues. The detailed analysis
of the methylation state of quite a large region of the galec-
tin-1 gene represents a useful contribution to studies of the
relationship between methylation and transcription and may
also provide insight into the mechanisms by which DNA
methylation regulates gene expression in tissues.
2. Materials and methods
2.1. Isolation of nucleic acids from tissues
The rodents used in this study were Sprague-Dawley rats and C57/
B16 mice. Genomic DNA was prepared from freshly minced tissues
by a standard phenol-chloroform extraction method [25].
2.2. CD-PCR
Cytosine deamination by bisul¢te treatment of single-stranded
DNA and subsequent PCR ampli¢cation (CD-PCR) was done essen-
tially as described by Frommer et al. [26]. An 8-Wg sample of genomic
DNA was ¢rst digested with EcoRI or with XbaI and then denatured
in 0.3 M NaOH for 15 min at 37‡C in a volume of 100 Wl, and then
60 Wl of 10 mM hydroquinone and 1.04 ml of 3.6 M sodium bisul¢te
(pH 5) were added. The reaction mixtures were incubated at 50‡C for
16 h in the dark. The DNA was desalted and concentrated with
Geneclean (Bio101), desulfonated with 0.3 M NaOH for 15 min at
37‡C, neutralized with 3 M ammonium acetate (pH 7) and ethanol
precipitated. Unmethylated C is changed to U while m5C remains as
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C. An aliquot of DNA was ampli¢ed by using modi¢ed primers (see
below). All PCRs were carried out in 100-Wl volumes containing
10 mM Tris, 50 mM KCl, 1 mM MgCl2, 5% dimethyl sulfoxide,
0.2 mM deoxynucleoside triphosphates, 10 pmol of each primer,
and 2 U of Taq polymerase (Stratagene). The ampli¢cation cycles
were as described elsewhere [27]. The ampli¢ed fragments were cloned
into the pCRII vector of the TA cloning system (Invitrogen), and then
several independent clones for each fragment were sequenced by using
the T7 and/or universal primer (Novagen) to determine the methyl-
ation pattern of individual molecules.
2.3. Determination of primers for CD-PCR
The sequence of the rat galectin-1 promoter region from position
3624 to +745 (Accession number: U40624) has been determined by
partial sequencing of two overlapping genomic fragments isolated by
screening a rat genomic library (Clontech): StuI-XbaI (from positions
3624 to +450) and EcoRI (from positions 360 to +2800). Sequencing
reactions were carried out by the dideoxynucleotide chain-termination
method [28] with a T7 sequencing kit (Pharmacia). Primers U2, U1,
L1 and L2, used in a previous study [22], correspond to the following
regions: positions 3205 to 3177 and +93 to +120 for the ampli¢ca-
tion of the upper strand and positions 3124 to 397 and +87 to +114
for the lower strand. New oligonucleotides (U3, U4, U5 and U6) were
designed as complementary to sodium bisul¢te-treated rat DNA ac-
cording to the criteria speci¢ed by Frommer et al. [26]. Modi¢ed
primers were: U3 from positions 3199 to 3169 (5P-ACCCCTCTC-
TTAAATCCCTCCCTCAAAATCC-3P) ; U4 from positions 3618 to
3588 (5P-GGTGTTTAGTTAGTTTTAGTGAGTAGTATTG-3P) ;
U5 from positions +725 to +754 (5P-CATTACAC ACAACTACC-
TAAATAAATACAC-3P) and U6 from positions +295 to +323 (5P-
TGAGTTGTGGTATGTTTTGTAAGGTTTAG-3P). Primers, cho-
sen on the basis of the mouse genomic sequence [15], correspond to
the following regions: positions +98 to +125 and 3205 to 3178 for
the ampli¢cation of the upper strand and positions 3124 to 397 and
+92 to +119 for the lower strand. Modi¢ed primers were: MU2 (5P-
GTGTTAGGATTTTGAGGGAGGGGTTAGG-3P) ; MU1 (5P-TT-
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Fig. 1. Analysis of clones derived from the galectin-1 promoter region after bisul¢te treatment. A: Methylation analysis of representative clones
derived from the top strand of the galectin-1 promoter region of rat skeletal muscle (left) and brain (right). B: Methylation analysis of repre-
sentative clones derived from the top strand of the galectin-1 promoter region of mouse skeletal muscle (left) and from the bottom strand of
mouse brain (right). Genomic DNAs from the di¡erent tissues were treated with sodium bisul¢te, ampli¢ed, and cloned into the pCRII vector.
Plasmids were sequenced reading the upper strand of the original DNA in the 3P-to-5P direction and the lower strand in the 5P-to-3P direction.
U’s, derived from unmethylated C’s appear as T’s (lower strand) or as A’s (upper strand) while m5C’s appear as C’s (lower strand) or as G’s
(upper strand). C: Alignment of the rat and mouse galectin-1 promoter sequences. Identical residues in the mouse sequence are indicated by
dashes, the CpG dinucleotides are shaded, and the consensus elements are underlined. Numbering refers to the rat sequence, the transcribed se-
quence corresponding to the ¢rst exon is in capital letters and the amino acids corresponding to the ¢rst three coding triplets are indicated.
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CTACTCAATCCCCTAAACCTTAAAAC-3P) ; ML1 (5P-TCCATA-
AACTCCACTTCTAATAACCCCC-3P) and ML2 (5P-TTAGTTTTT-
TAGATTTTGGAATAGAGGG-3P).
2.4. In vitro DNA methylation and gel-retardation assay
The galectin-1 promoter fragment from positions 350 to +50 was
obtained by excision from the pGAT50 plasmid [21]. The fragment
(10 Wg) was treated with 8 U of SssI methylase (New England Bio-
labs) at 37‡C in the presence of 5 mM adenosylmethionine for 8 h.
Complete methylation of treated plasmid was con¢rmed by HpaII
restriction enzyme digestion. Methylated and unmethylated fragments
were used as probes for binding reactions. The labelling reaction was
performed with T7 polynucleotide kinase (Boheringer-Mannheim) and
[Q-32P]dATP. Gel shift assays were performed as described elsewhere
[29]. Samples were loaded on 5% nondenaturing polyacrylamide gels.
The gels were then dried and subjected to autoradiography.
3. Results
3.1. Methylation of CpG sites in the galectin-1 promoter region
We examined the methylation state of the galectin-1 gene
promoter region in rat tissues in which galectin-1 expression
was very high (skeletal muscle) and very low (brain and liver)
([1,15] and data not shown). The promoter regions of the rat,
mouse and human galectin-1 genes contain a conserved cluster
of CpG dinucleotides surrounding the transcription initiation
site [22]. Fig. 1C shows an alignment of the rat and mouse
sequences complete with their relevant features including the
relative position of CpG sites. The methylation state of all the
CpG doublets of the cluster of the rat gene from positions
3122 to +81 was analyzed in the di¡erent tissues by genomic
sequencing. This region was previously found to be fully
methylated at every CpG site in nonexpressing rat liver cell
lines and fully unmethylated in human osteosarcoma express-
ing cells and in reactivated rat alleles in cell hybrids [22]. We
used two sets of primers each speci¢c for the upper (U1 and
U2) and the lower (L1 and L2) strands of bisul¢te-treated
DNA for the analysis of the methylation state of 11 and 9
dinucleotides, respectively. DNAs from the nonexpressing liv-
er and brain, and from expressing skeletal muscle were sub-
jected to CD-PCRs. The ampli¢ed fragments were cloned and
several plasmid clones derived from each tissue were analyzed
by DNA sequencing. Representative sequence pro¢les of rat
skeletal muscle and brain are presented in Fig. 1A; the sta-
tistical analysis of all the experiments is shown in Fig. 2A. The
galectin-1 promoter region was consistently methylated in
brain and liver, and mostly unmethylated in skeletal muscle.
However, the methylation pro¢les of the CpG sites in rat
tissues were more complex than those observed in cell lines
[22]. In particular, sites at positions 3122, 3113, 363, 353,
314, +7, +41, +55 on the top strand were fully unmethylated
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Fig. 2. Percentage of DNA methylation at individual CpG sites in the galectin-1 promoter. Data obtained from genomic sequencing of bisul-
¢te-treated DNA were compiled by individual CpG dinucleotides and expressed as the ratio of methyl-C to the number of clones. A: Rat tis-
sues: brain (open bars); liver (gray bars); and skeletal muscle (black bars). The relative position of CpG dinucleotides (vertical lines) and of
the ¢rst exon (open box) of the rat galectin-1 gene is indicated between the upper (top strand) and the lower (bottom strand) panels. B: Mouse
tissues: brain (open bars); skeletal muscle (black bars). The mouse galectin-1 region is depicted as in A.
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in muscle and variably methylated in brain and liver. A very
low level of methylation compared with that observed in brain
and liver was present at some sites on the bottom strand in
skeletal muscle. The sites at positions 343 and 319 were
unmethylated or hypomethylated on both strands in express-
ing and nonexpressing tissues. Strikingly, the last site of the
cluster, at position +81, was almost fully methylated in all
tissues. The methylation pattern of the top and bottom
strands was almost symmetrical in each of the di¡erent tissues
(Fig. 2A).
With the bisul¢te genomic sequencing technique, each plas-
mid clone is representative of a single allele each derived from
a di¡erent cell [26]. Therefore, by this procedure it was pos-
sible to appreciate a high heterogeneity of the methylation
patterns within the nonexpressing tissues (see examples shown
in Fig. 1AFig. 3A and B). Fig. 3 shows the methylation pat-
terns of each individual molecule analyzed for rat brain (A),
liver (B) and muscle (C) top strands. It is apparent that there
was no correlation between the methylation at one site and
methylation at other CpGs in the same DNA strand and that
methylation of a site is independent of its neighbors. More-
over, in rat brain and liver every molecule had at least two
methylated CpGs whereas in rat muscle no molecule had
more than one. The same features were observed for the lower
strands (data not shown).
To verify whether the methylation pro¢les observed in rat
were conserved in another species, we performed the same
analysis with mouse skeletal muscle and brain using appro-
priate primers on bisul¢te-treated mouse genomic DNAs.
Representative sequence pro¢les of skeletal muscle and brain
are shown in Fig. 1B, and a statistical analysis of all the
experiments performed is presented in Fig. 2B. Although the
overall level of methylation was lower than in rat, the general
pattern of methylation was similar, including the high degree
of heterogeneity and the random distribution of methylated
CpGs (Fig. 1B and data not shown). The last site of the
mouse CpG cluster at position +87 was again almost fully
methylated on both strands in expressing and nonexpressing
tissues (Fig. 2B).
3.2. Limits of the di¡erentially methylated genomic region
To establish the spatial limits of the genomic region a¡ected
by changes in the CpG modi¢cation state we designed two
sets of primers (U3^U4 and U5^U6), each speci¢c for upper
strand ampli¢cation of the galectin-1 gene region from posi-
tions 3587 to 3200 including 11 CpGs, and from positions
+324 to +724 including 7 dinucleotides, respectively (Fig. 4).
DNAs from brain and skeletal muscle were subjected to CD-
PCRs and the ampli¢ed fragments were cloned. At least 15
plasmid clones for each fragment were subjected to sequenc-
ing reactions. An analysis of the entire region from positions
3587 to +724 of rat brain and skeletal muscle is shown in Fig.
4A and B, respectively. The methylation pattern of the two
tissues was similar in the genomic regions £anking the di¡er-
entially methylated CpG cluster. Several sites were constantly
unmethylated in both tissues, while others were infrequently
(6 25%) and, in general, not di¡erentially methylated. These
results demonstrate that the changes in CpG methylation in
expressing and nonexpressing rat tissues are con¢ned to the
CpG cluster lying around the transcription start site.
3.3. Methylation of the core promoter does not directly inhibit
the binding of nuclear factors
A galectin-1 promoter fragment from positions 350 to +50,
containing 4 CpG sites, was previously demonstrated to be
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Fig. 3. Variation in DNA methylation in individual PCR clones
from the galectin-1 promoter. All the sequenced molecules from rat
brain (A), liver (B) and muscle (C) upper strands are shown. Num-
ber of clones from muscle exhibiting the same pattern is indicated
in parentheses. Numbers on top show location of CpG dinucleotides
(boxes). Black boxes indicate that the corresponding cytosines are
methylated.
Table 1
Average of methylated sites per chromosome in the galectin-1 pro-
moter region in rat (from position 3122 to +81) and mouse (from
position 362 to +87) tissues
Tissues* Top strand Bottom strand
Rat brain 3.6 (22) 4.1 (18)
Mouse brain 2.1 (21) 3.5 (20)
Rat liver 3.0 (21) 3.1 (18)
Rat muscle 0.9 (25) 1.5 (20)
Mouse muscle 1.0 (18) 1.2 (20)
*The numbers of clones analyzed for each tissue are reported in pa-
rentheses.
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su⁄cient to drive e⁄cient transcription and to bind still un-
identi¢ed nuclear factors present in expressing (NIH3T3) and
nonexpressing cell lines [21]. In vitro methylation of the 4
CpG sites strongly inhibited the transcriptional activity in
mouse ¢broblasts [22]. To investigate whether modi¢cation
of CpG sites contained in the minimal promoter region inter-
feres with the binding of transcription factors, we performed
mobility shift experiments using as probes the core promoter
fragment either unmethylated or in vitro methylated at each
CpG site. Both probes formed a complex with the NIH3T3
nuclear extracts and the pattern of retarded bands was iden-
tical (Fig. 5, lanes 1 and 2). Moreover, the complex was spe-
ci¢cally inhibited by the addition of a 50-fold molar excess
of unlabelled 350 to +50 fragment both methylated (Fig. 5,
lane 3) and unmethylated (data not shown). These ¢ndings
indicate that the fully methylated core promoter is still able
to bind nuclear factors and, therefore, that mechanisms other
than simple direct interference by DNA methylation with the
binding of activators must be involved in the putative meth-
ylation-mediated silencing of galectin-1 gene.
4. Discussion
We previously de¢ned the galectin-1 gene promoter region
[21] and showed that regulation of transcription in cell lines is
controlled by DNA methylation [22]. The aim of the present
study was to investigate whether DNA methylation correlates
with transcription also in expressing and nonexpressing tissues
and to establish the range of the region exhibiting di¡erences
in the methylation pattern. We used bisul¢te genomic se-
quencing to obtain a high resolution map of the methylation
state of several CpG sites that span a large portion of the
galectin-1 gene. We found that in the high expressing rat
and mouse skeletal muscle, most of the CpG sites in the clus-
ter spanning the transcription start site were fully unmethyl-
ated with the notable exception of the last site which was
nearly 100% methylated (Fig. 2). Because most of the CpG
sites of the cluster were methylated in nonexpressing tissues,
we conclude that methylation is correlated with repression of
galectin-1 gene. Analysis of the entire region from positions
3587 to +724 of the rat galectin-1 gene in di¡erent tissues
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Fig. 4. Percentage of DNA methylation at individual CpG sites in the rat galectin-1 gene region from positions 3587 to +724. Methylation
analyses of rat brain top strand (A) and skeletal muscle top strand (B) are presented. The analyses shown in the ¢gure summarize the results
obtained for the region from positions 3122 to +81 (presented in Fig. 2) and data obtained for the £anking regions. Calculations were per-
formed and expressed as reported for Fig. 2. The positions of the 29 CpG sites analyzed are indicated at the bottom of each panel. The posi-
tions of the synthetic oligonucleotides used for the CD-PCR analysis are indicated at the bottom of the ¢gure.
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showed that di¡erences in CpG methylation state in the ex-
pressing and nonexpressing tissues were con¢ned to the CpG
cluster encompassing the transcription start site (Fig. 4). In
striking contrast, Southern blot and genomic sequencing ex-
periments revealed that the entire region from position 3587
to +724 was heavily methylated in nonexpressing cell lines and
unmethylated in the reactivated galectin-1 alleles in cell hy-
brids ([22] and unpublished data).
We observed other notable di¡erences in the methylation
state of the galectin-1 promoter region between cell lines and
tissues. Earlier studies on expressing cell lines and on human-
rat cell hybrids [20,22] demonstrated that in the active or
reactivated galectin-1 alleles, all the CpG sites of the cluster
are fully unmethylated including the last site which, on the
contrary, was almost totally methylated in muscle tissue. All
the CpGs of the cluster are fully methylated in a nonexpress-
ing cell line (FAO) [22]. Conversely, a variable level of meth-
ylation was observed in most of the CpG sites of the cluster in
nonexpressing liver and brain tissues. The heterogeneous pat-
terns of methylation in nonexpressing tissues might indicate
that methylation contributes less in silencing of the gene in
tissues compared to cell lines. Alternatively, the galectin-1
gene is regulated by methylation in both cell lines and tissues,
but while in the cell lines the methylation of the gene is an all-
or-none phenomenon, in tissues it is much more ¢nely tuned.
Central to our understanding of the biological role of DNA
methylation is the elucidation of mechanisms by which the
CpG modi¢cation a¡ects gene activity, and of the mechanisms
by which a cell ‘decides’ that speci¢c sequences be methylated
or unmethylated. It is believed that DNA methylation can
in£uence gene activity: (i) by directly a¡ecting the binding
of transcription factors [30] ; (ii) through the binding of meth-
yl-C binding proteins [31,32] ; or (iii) by altering the chromatin
structure [33]. Very recently Nan et al. [34] demonstrated that
a speci¢c methyl-C binding protein, MeCP2, can act as a
repressor on methylated promoters and that this activity de-
pends on the number of methylated CpG sites within a given
region. Repression ¢rst appears when the density of methyl-
ated sites in a promoter region approaches 1 per 100 bp [34].
Our genomic sequencing analysis indicates that in spite of the
highly heterogeneous nature of the promoter methylation pro-
¢les the average of methylated sites in the galectin-1 promoter
is over 1/100 bp in nonexpressing tissues and less than 1/100
bp in expressing tissues (Table 1). This feature is conserved in
rat and in mouse galectin-1 promoter. It appears that each cell
of a given tissue does not obey precise rules to control the
methylation state of speci¢c sites, but what could be critical is
that, as a result of methylation and demethylation events, at
least two of the 11 CpG sites in the 3122/+81 region remain
methylated in each cell and this would result in repression of
the gene. This hypothesis is substantiated by the ¢nding of a
very heterogeneous methylation pattern in some of the few
tissue-speci¢c genes analyzed by genomic sequencing, i.e. pro-
lactin and growth hormone [35]. In addition, we found that
methylation does not interfere with binding of nuclear factors,
even on a fully methylated galectin-1 core promoter (Fig. 5),
in keeping with the proposal that methyl-C binding proteins
can act as repressors without altering the binding of transcrip-
tion factors [34].
Finally, an interesting ¢nding of our study is the presence,
despite the heterogeneity in the methylation pro¢les, of a con-
stant full methylation of a single site within the 1300 bp re-
gion analyzed, the last of the CpG cluster located around the
transcription start site (Fig. 4). This feature is conserved in
expressing and nonexpressing tissues and in mouse and in rat.
Thus, it is likely that the methylation of this site has a precise
function. An attractive hypothesis is that a CpG site in its
methylated state could be a recognition element for transact-
ing factors, which have been postulated to be involved in
regulating the methylation and demethylation of a de¢ned
DNA region [36^38].
We are currently investigating the role of methyl-CpG den-
sity in modulating the activity of the galectin-1 gene and the
relative contribution of each of the di¡erent elements in de¢n-
ing the methylated and unmethylated state of the galectin-1
promoter region.
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